Search for content, post, videos

Last patient included in AlzeCure’s Phase II trial

The last patient has now been included in the ongoing clinical study with ACD440, the lead non-opioid drug candidate in the painless platform, which is being developed against peripheral neuropathic pain. This double-blind, placebo-controlled, randomized cross-over study, which is carried out in
Already a subscriber Login

You have read all your free articles, to continue reading subscribe to read the rest of this content.